Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during herceptin therapy.
We studied the effect of Herceptin therapy on the population composition of lymphocytes and percentage of CD4+CD25+ cells (regulatory T cells) in breast cancer patients. Herceptin treatment decreased the number of "professional" T suppressors (CD4+CD25+ cells and regulatory T cells) in the peripheral blood.
Slavina
E G
EG
N. N. Blokhin Russian Cancer Research Center, Moscow.
Chertkova
A I
AI
Zabotina
T N
TN
Gan'shina
I P
IP
Lichinitser
M R
MR
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D015704:CD4 Antigens / Q000276:immunology*; D005260:Female; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology*; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015704:CD4 Antigens; D053645:Interleukin-2 Receptor alpha Subunit; D000068878:Trastuzumab